Endovascular options for the treatment of femoropopliteal peripheral arterial disease are limited. Current standard of care is usually to perform a percutaneous transluminal angioplasty (PTA) with provisional bare-metal stent (BMS) as needed. The current trial sought to study the safety and efficacy of stenting with a polymer-free paclitaxel-eluting Zilver PTX stent, as compared with PTA alone for the treatment of such lesions.